A Systematic Review of Conversion to Resectability in Unresectable Metastatic Colorectal Cancer Chemotherapy Trials
GastroenterologiaSobre o estudo
- Desenho
- Revisão sistemática
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- American journal of clinical oncology
- Publicado em
- 15 jul 2022
- Citações
- 11
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
A Systematic Review of Conversion to Resectability in Unresectable Metastatic Colorectal Cancer Chemotherapy Trials
Sarah Chrabaszcz, Rahul Rajeev, Hunter D D Witmer, Ankit Dhiman, Brittany Klooster, T Clark Gamblin, Anjishnu Banerjee, Fabian M Johnston, Kiran K Turaga
Descritores MeSH
- Colorectal Neoplasms
- Colonic Neoplasms
- Rectal Neoplasms
- Camptothecin
- Leucovorin
- Bevacizumab
- Fluorouracil
- Humans
- Cetuximab
- Antineoplastic Combined Chemotherapy Protocols
Veja também
Estudos relacionados
- Delta tocotrienol as a supplement to FOLFOXIRI in first-line treatment of metastatic colorectal cancer. A randomized, double-blind, placebo-controlled phase II study
- FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study
- Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306
- Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3